EP1465619A1 — Suppression of cartilage degradation via the estrogen receptor
Assigned to Nordic Bioscience AS · Expires 2004-10-13 · 22y expired
What this patent protects
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to th…
USPTO Abstract
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.